AVITA Medical Demonstrates First Integrated Use of Three Advanced Wound Care Technologies at Boswick Symposium
核心洞察
Surgeons reported the first integrated use of RECELL (搜索), PermeaDerm (搜索), and Cohealyx (搜索) technologies in challenging wound cases, demonstrating a comprehensive staged care approach for complex wounds.
New histological data from clinical trials showed PermeaDerm (搜索) supported organized tissue formation without increased inflammation, while Cohealyx (搜索) promoted cellular infiltration and blood vessel formation within two weeks.
A systematic review of 27 studies confirmed RECELL (搜索)'s clinical benefits, including smaller donor sites, faster healing times, and reduced hospital stays by up to 16 days in elderly burn patients.
AVITA Medical presented compelling new data at the 2026 Boswick Burn & Wound Symposium, showcasing the first surgeon-reported integrated use of all three company technologies and reinforcing the clinical benefits of its wound care platform through comprehensive real-world evidence.
Breakthrough in Integrated Wound Care
The symposium featured the first documented case series demonstrating the combined use of RECELL (搜索), PermeaDerm (搜索), and Cohealyx (搜索) in individual patient care pathways. Surgeons described treating two challenging cases - a young trauma patient and an elderly patient with a large full-thickness wound - using a staged approach that integrated all three technologies.
The treatment protocol involved PermeaDerm (搜索) for initial wound coverage, Cohealyx (搜索) to prepare the wound bed for closure, and RECELL (搜索) combined with skin grafting for final healing. This integrated approach reduced the need for frequent, painful dressing changes and eliminated long-distance follow-up appointments, offering particular benefits for rural and community hospitals with limited access to specialized burn services.
Clinical Trial Data Reveals Tissue-Level Benefits
New histological findings from ongoing multicenter clinical trials provided insights into how AVITA Medical's technologies support wound healing at the cellular level. Data from the PermeaDerm (搜索) I clinical trial showed that the biosynthetic wound matrix supported early blood vessel growth and more organized tissue formation compared with donated human skin commonly used for temporary coverage. Critically, this occurred without increased inflammation, which can interfere with healing processes.
Similarly, initial results from the Cohealyx (搜索) I clinical trial demonstrated the collagen-based dermal matrix's ability to support cellular infiltration and early blood vessel formation within two weeks. In the reported case, these tissue changes allowed the wound to become ready for skin grafting without complications.
Comprehensive Evidence Base Confirms RECELL Benefits
A systematic review led by Dr. Anju Bakhshi Saraswat examined outcomes across 27 peer-reviewed studies comparing RECELL (搜索)-based treatment with conventional wound closure approaches, including split-thickness skin grafting. The analysis revealed consistent advantages for RECELL use, including smaller donor sites, similar or faster healing times, improvements to pain and appearance outcomes, and more favorable health economic outcomes.
Real-world registry data reinforced these findings with particularly striking results in vulnerable patient populations. Among burn patients aged 65 and older, adding RECELL (搜索) to standard skin grafting was associated with fewer graft failures and hospital stays that were nearly 16 days shorter among patients who survived to discharge.
A separate national registry analysis of adults with deep partial-thickness burns (搜索) showed that patients treated with RECELL (搜索) spent approximately one-third less time in the hospital than those receiving traditional grafting. These patients were also more likely to be discharged directly home, suggesting improved recovery outcomes.
Clinical Impact and Future Implications
The consistency of findings across comparative studies, real-world analyses, and higher-risk patient populations demonstrates that RECELL (搜索) performs predictably in routine clinical practice. This evidence base supports the technology's role as a foundational component of staged wound care strategies.
"Across these presentations, surgeons are demonstrating how staged use of our advanced wound care technologies, either independently or together, can improve healing while helping hospitals manage limited resources," said Cary Vance, Interim CEO of AVITA Medical.
The data presented at the symposium encompassed 19 scientific abstracts, including 14 podium presentations, representing one of the most comprehensive evidence presentations for AVITA Medical's wound care platform to date. Full results from the ongoing PermeaDerm (搜索) I and Cohealyx (搜索) I clinical trials are expected in 2026.